TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02316223

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supporting Asthma Management Behaviors in Aging Adults (SAMBA)
Description: The SAMBA program will be led by an asthma care coach (ACC) and the home program by a community health worker (CHW). All interventions, including usual care, will include EMR-based asthma self-management and decision support tools for clinicians in all practice sites. The ACC and CHW will provide education, goal setting, and general self-management support with assigned patients and coordinate with PCPs through in-person and phone contacts over 12 months. Outcomes will be measured through interviews, EMR chart abstractions, and from the Statewide Planning and Research Cooperative System (SPARCS) dataset to identify all ED visits and hospitalizations to any New York State facility.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supporting Asthma Management Behaviors in Aging Adults (SAMBA)
Description: The SAMBA program will be led by an asthma care coach (ACC) and the home program by a community health worker (CHW). All interventions, including usual care, will include EMR-based asthma self-management and decision support tools for clinicians in all practice sites. The ACC and CHW will provide education, goal setting, and general self-management support with assigned patients and coordinate with PCPs through in-person and phone contacts over 12 months. Outcomes will be measured through interviews, EMR chart abstractions, and from the Statewide Planning and Research Cooperative System (SPARCS) dataset to identify all ED visits and hospitalizations to any New York State facility.
Study: NCT00446966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega Three Polyunsaturated fatty acids
Description: 2 grams orally twice daily pre-operatively and 2 grams orally daily after until primary endpoint or 14 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Omega Three Polyunsaturated fatty acids
Description: 2 grams orally twice daily pre-operatively and 2 grams orally daily after until primary endpoint or 14 days.
Study: NCT03703154

Intervention type: DRUG
Intervention: Envarsus
Description: Patients will then be randomized in the ratio of 2:1 with 20 being in the study arm and 10 in the control arm. Envarsus will be prescribed by the transplant team per conversion guidelines. The transplant team will monitor drug levels, per the dosing guidelines.

Intervention type: DRUG
Intervention: Tacrolimus
Description: The patient's physician will prescribe drug according to standard practice.
Study: NCT01169753

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet every morning for 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armodafinil
Description: Three 50 mg tablets orally every morning for 2 weeks.
Study: NCT01943877

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: scaling root planing
Description: scaling root planing

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: scaling root planing
Description: scaling root planing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propolis
Description: experimental
Study: NCT03084263

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopic Assisted Open Reduction Internal Fixation
Description: Surgical fixation of ankle fractures with use of arthroscopy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Reduction Internal Fixation
Description: Surgical fixation of ankle fractures.
Study: NCT03489629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethoprim Sulfamethoxazole (TMP/SMX)
Description: Dosing if \< 40 kg: 8 mg/kg trimethoprim/40 mg/kg trimethoprim sulfamethoxazole given twice daily for 14 days during Days 1-14 and Days 29-42.~Dosing is ≥ 40 kg: 320 mg/1600 mg twice daily for 14 days during Days 1-14 and Days 29-42.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: If a subject has an allergy to or intolerance to TMP/SMX, they may be treated with minocycline provided they are 8 years of age or older.~Dosing if \< 50 kg: 2 mg/kg orally twice daily for 14 days during Days 1-14 and Days 29-42.~Dosing if ≥ 50 kg: 100 mg twice daily for 14 days during Days 1-14 and Days 29-42.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mupirocin
Description: 1 gram 2% nasal ointment generously applied to each nostril using a cotton swab twice daily for 5 days during Days 1-5 and Days 29-33.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine Gluconate
Description: For subjects able to swish without swallowing, 0.12% chlorhexidine gluconate oral rinse will be used twice daily for 14 days during Days 1-14 and Days 29-42.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Environmental Decontamination
Description: Subjects will be instructed to wipe down all high touch surfaces and medical equipment with surface disinfection wipes daily during Days 1-21 and Days 29-49.~Subjects will also be instructed to wash all linens and towels in hot water once weekly during weeks 1-3 and weeks 5-7.
Study: NCT01167829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Testosterone
Description: Oral Testosterone: 300 mg, pills, three times daily Day 1 - 10 (total of 27 pills)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acyline
Description: 300 ug/kg injection on Day 0
Study: NCT01828125

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hypoglycaemic hyperinsulinemic clamp
Description: A first catheter will be inserted for infusion of D-\[6,6-2H2\] glucose and insulin. A second catheter will be inserted for infusion of dextrose. Dextrose infusion will be enriched with D-\[6,6-2H2\] glucose. A third catheter will be inserted for sampling. D-\[6,6-2H2\] glucose will be administered as a priming dose followed by a constant infusion throughout the experiment. Insulin will be administered as a primed continuous infusion. The first two hours will serve as an equilibration period for the tracer while glucose infusion will be adjusted to achieve a plasma glucose concentration of 5 mmol/L. The third hour is considered the baseline period. Following this, dextrose infusion rate will be decreased over a period of 1 hour to attain hypoglycaemia with a target blood glucose level at 2.8 mmol/L. At the end of the fourth hour, a subcutaneous glucagon dose will be given and plasma samples will be drawn for the determination of labelled and unlabelled glucose, plasma insulin and glucagon.
Study: NCT01789463

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self rehabilitation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self rehabilitation plus physiotherapy
Study: NCT00573950

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet comparable to 50mg cilostazol two times a day for 2 weeks and then placebo tablet comparable to 100mg cilostazol two times a day for 6 weeks
Study: NCT01388374

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Other, care provided by Nurse Practitioners
Description: Patients will receive care at the Primary Out of Hours Emergency Service by a Nurse Practitioner instead of a General Practitioner (substitution of care from physicians to nurses).
Study: NCT04303884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Injection [Keytruda]
Description: Pembrolizumab administration at a fix dose of 200 mg every 3 weeks
Study: NCT03516539

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Group ML
Description: Mcgrath videolaryngoscope
Study: NCT02580773

Intervention type: DRUG
Group type: OTHER
Intervention: Prophylactic anticoagulation ( INNOHEP®)
Description: subcutaneous anticoagulation with low molecular weight heparin (tinzaparin) at a prophylactic dose (4500 UI/day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curative anticoagulation ( INNOHEP®)
Description: subcutaneous anticoagulation with low molecular weight heparin (tinzaparin) at a curative dose (175 UI/kg/day for 7 days)
Study: NCT02026973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Study: NCT03516539

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Group DL
Description: Macintosh laryngoscope
Study: NCT02026973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT00572481

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Axillary Reverse Mapping
Description: During surgery, the technetium-99m sulfur colloid will be injected into the breast and the blue dye injected (if the patient is not allergic and it is not required to locate the SLN) in the patient's ipsilateral upper arm. The lymph node biopsy and/or dissection will be performed by the surgeon, according to standard practice.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Axillary Reverse Mapping
Description: During surgery, the technetium-99m sulfur colloid will be injected into the breast and the blue dye injected (if the patient is not allergic and it is not required to locate the SLN) in the patient's ipsilateral upper arm. The lymph node biopsy and/or dissection will be performed by the surgeon, according to standard practice.
Study: NCT03913377

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectacles
Description: Subjects' own habitual spectacles

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectacles
Description: Subjects' own habitual spectacles
Study: NCT01828125

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon
Study: NCT03913377

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACUVUE OASYS®1-Day with HydraLuxe™ Technology
Description: Test 1
Study: NCT03196258

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy
Description: Participants who are randomized to the CBT intervention are required to start CBT within 8 weeks of their fracture surgery. The CBT intervention will consist of 6 weekly one-on-one, 1-hour sessions that will focus on addressing maladaptive beliefs related to pain and recovery as well as teaching skills to enhance coping and management of pain symptoms. The specific focus of CBT sessions will be informed by each individual patient's responses on the SPOC questionnaire. All other aspects of post-operative care will be at the discretion of participant's surgeon
Study: NCT04018404

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FRI CLINICAL PROGRAM
Description: University Le Bonheur Pediatric Specialists and Le Bonheur Community Health and Well-Being, Maternal Child Department, have started the Family Resilience Initiative (FRI) in the ULPS General Pediatrics Clinic. This clinical program screens children 9 months to less than five years of age for ACES and SDH at the time of presentation for well child checks. There are two outreach coordinators who screen and enroll children attending clinic for a well-child check during morning clinics 3 to 4 days per week. Children with positive screens for ACES and/or SDH, and their adult caregivers, receive community resource referrals with warm handoffs to vetted organizations. In addition, if indicated, psychological services are offered for children based upon the presence of one or more of ACEs and current health and behavioral problems.
Study: NCT02278809

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Movie Models
Description: The intervention group got acces to a private website for 4 weeks on which the online videos were placed (Week 1: fruit + water, week 2: vegetables + breakfast + supermarket, week 3: PA, week 4: SB)~After each week, parents received a link for an online process evaluation questionnaire in which we asked how many times they watched each video, if they discussed the videos with other people, if they found them interesting, boring...
Study: NCT02736123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab - Arm A
Description: Nivolumab will be given during the induction phase of the study for 6 weeks. This is followed by surgery. Then maintenance therapy (after recovery from surgery).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab + Ipilimumab - Arm B
Description: Nivolumab + ipilimumab during the induction phase of the study for 6 weeks. This is followed by surgery (week 6-8+). Then maintenance therapy will be initiated for up to one year from study drug initial administration ((after recovery from surgery).
Study: NCT00042874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alvocidib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02105272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-1085EL ophthalmic solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost ophthalmic solution
Study: NCT03135236

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent training
Description: Participants will attend 3 trainings. There will be a pre-test before training 1 and an initial post-test after training 3. There will be a final post-test 1 month after the final training.
Study: NCT02026973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatostatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatostatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatostatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatostatin
Study: NCT02167152

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ischemic preconditionin
Description: Ischemic preconditioning will be accomplished through 4 cycles of alternating 5-minute inflation and 5-minute deflation of an upper-arm blood pressure cuff to the patient's systolic blood pressure plus 50% to induce ischemia and reperfusion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ischemic preconditionin
Description: Ischemic preconditioning will be accomplished through 4 cycles of alternating 5-minute inflation and 5-minute deflation of an upper-arm blood pressure cuff to the patient's systolic blood pressure plus 50% to induce ischemia and reperfusion.
Study: NCT01592695

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine replacement therapy - transdermal nicotine patch
Description: Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
Study: NCT03600883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sotorasib
Description: Characterize the pharmacokinetics (PK) of sotorasib following administration as an oral Tablet formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sotorasib
Description: Characterize the pharmacokinetics (PK) of sotorasib following administration as an oral Tablet formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sotorasib
Description: Characterize the pharmacokinetics (PK) of sotorasib following administration as an oral Tablet formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sotorasib
Description: Characterize the pharmacokinetics (PK) of sotorasib following administration as an oral Tablet formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sotorasib
Description: Characterize the pharmacokinetics (PK) of sotorasib following administration as an oral Tablet formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sotorasib
Description: Characterize the pharmacokinetics (PK) of sotorasib following administration as an oral Tablet formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti PD-1/L1
Description: Administered as an intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Administered as an oral hydrochloride (HCI) syrup
Study: NCT01592695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy - transdermal nicotine patch
Description: Medication selection will be determined based on individual participant preferences, medical history, and contraindications.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored behavioral intervention
Description: Participants will receive a standard six session cognitive behavioral intervention for smoking cessation combined with supplemental treatment modules based on individual need and preference.
Study: NCT01720667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous levetiracetam
Description: Intravenous load of levetiracetam (40 to 60 mg/kg) following identification of EEG confirmed neonatal seizure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous phenobarbital
Description: Intravenous load of phenobarbital (20 to 40 mg/kg) following EEG confirmation of seizure activity load.
Study: NCT01304862

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eSMART-MH intervention
Description: Involves simulated interactions between participants and the virtual health care providers (avatars).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational videos about healthy living
Description: 20 minute screen-based educational videos on topics about healthy living--nutrition, physical activity, and sleep hygiene.
Study: NCT03683199

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rhinoplasty
Description: The cleft lip rhinoplasty will be performed under general anesthesia.~1: 100,000 epinephrine will be infiltrated in the columellar incision and in the septum.~Open approach rhinoplasty will be used. A step ladder incision placed at the patient's columella, and continued with infra-cartilaginous incision.~The columellar skin flap along with the nasal tip skin will be dissected from the lower lateral cartilages.~Harvesting of the septal cartilage, to be used as spreader graft and columellar graft. Correction of the septal deviation.~Lengthening of the columella on the expense of the ala. Correction of the nasal tip by suturing techniques and by cartilage grafts.
Study: NCT02563431

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SYSTAM - SP-ED
Description: * Positioning in bed, wheelchair and standing with classics materials (pillow, holds, sling) on day J0 until J7 or Exit.~* Daily passive mobilisation of the upper member by a therapist.~* Be careful of shoulder's coaptation in care and functional activities (toilet, dressing, transfers)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasling ER 15°Donjoy - 4P-ED
Description: * Positioning in bed, wheelchair and standing with specific materials (holds, sling in external rotation and abduction) on day J0 until J7 or Exit.~* A training of the patient and members of family on pathology, risk, use of material~* Daily passive mobilization of the upper member by a therapist.~* Be careful of shoulder's coaptation in care and functional activities (toilet, dressing, transfers) and active patient training for use the other side for support hemiplegic shoulder to prevent diastasis.
Study: NCT01701635

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Disclosure intervention
Description: An adherence and disclosure specialist will meet with caregiver-child dyad at each clinic visit and provide caregiver information and skills for HIV disclosure till the caregiver discloses the HIV status to the child.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: An adherence and disclosure specialist will meet with caregiver-child dyad at each clinic visit and provide caregiver with general health information without referencing HIV disclosure in their conversations till the caregiver discloses the HIV status to the child.
Study: NCT02743754

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard therapy
Description: The standard of care for improving oxygen delivery to the kidney. These may include blood transfusions for anemia, treatment of low blood pressure and oxygen for low blood oxygen levels.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard therapy
Description: The standard of care for improving oxygen delivery to the kidney. These may include blood transfusions for anemia, treatment of low blood pressure and oxygen for low blood oxygen levels.
Study: NCT04407507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: ivermectin 12 mg / day for 3 days, in combination with standard paracetamol therapy (500 mg QID) for 14 days
Study: NCT02743754

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric Oxygen
Description: The standard of care therapies and in addition will be treated in the hyperbaric chamber within 12 hours of surgery. There will be 4 hyperbaric oxygen treatments in 48 hours (1 every 12 hours), each treatment will last 90 minutes with 100% oxygen at 2.4 ATA.
Study: NCT01678690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine HCl Oral Formulation
Description: Gemcitabine HCl Oral Formulation 80 mg/vial Subjects will be treated on Day 1 of the 7-day study treatment period
Study: NCT03811873

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Dual x-ray absorptiometry
Description: DEXA is a means of measuring bone mineral density (BMD) using spectral imaging. Two X-ray beams, with different energy levels, are aimed at the bones. Soft tissue absorption is subtracted out, then the bone mineral density (BMD) can be determined from the absorption of each beam by bone.
Study: NCT04407507

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo of ivermectin 12 mg / day for 3 days, in combination with standard paracetamol therapy (500 mg QID) for 14 days
Study: NCT03811873

Intervention type: OTHER
Group type: OTHER
Intervention: Vertebral Fracture Assessment
Description: Lumbar/thoracic spine x-ray and labs assessed for bone turnover markers.
Study: NCT02323360

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Patients with single nodule no more 5 cm or 1- 3 nodules no more 3 cm in diameter after incomplete TAE or TACE, are randomized to stereotactic radiotherapy in 3 or 6 daily fractions

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: Patients with single nodule no more 5 cm or 1- 3 nodules no more 3 cm in diameter after incomplete TAE or TACE, are randomized to a new cycle of TAE or TACE
Study: NCT02280083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A for Injection
Description: HengLi002(Botulinum Toxin Type A for Injection,also known as HengLi®)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo